| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8713788 | Journal of Allergy and Clinical Immunology | 2018 | 31 Pages |
Abstract
Our data demonstrate that TLR4 conditions induction of oral tolerance to DNFB through licensing tolerogenic gut DCs. Oral biotherapy with TLR4 ligands might be useful to potentiate oral tolerance to haptens and alleviate ACD in human subjects.
Keywords
TregFACSDLNFOXP3DTHSPFCHSeGFPDNFBMHC-IIACDMLNTLROVAMHC class IIOvalbumindelayed-type hypersensitivityOral toleranceContact hypersensitivityToll-like receptorforkhead box P3Germ freeAllergic contact dermatitiscontact dermatitisfluorescence-activated cell sortingRALDHRetinaldehyde dehydrogenaseDendritic cellDendritic cellsbone marrowRegulatory T Microbiotaspecific pathogen freeenhanced green fluorescent proteinDraining lymph nodemesenteric lymph nodeLymph nodeToll-like receptor 4
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Feriel PhD, Mercedes PhD, Reem MD, PhD, Ludovic PhD, Jean-Benoit PhD, Claire MSc, Gilles MD, PhD, Emilie BSc, Philippe PhD, Bertrand PhD, Dominique PhD,